Table 3. Comparison of Summary Estimates for Study Outcomes.

Outcome	Incidence: Bivalirudin, %/UFH, %	Model	Summary estimate (OR)	95% CI	P-value	I2%
Stent Thrombosis	1.2/0.8	P	1.49	1.15–1.92	0.002	16.9
		SGS	1.83	1.06–3.14	0.033
MACE	7.8/7.6	P	1.04	0.94–1.14	0.46	53.9
		SGS	1.12	0.81–1.55	0.448
Mortality	1.5/1.6	P	0.88	0.72–1.08	0.21	31.5
		SGS	0.76	0.48–1.18	0.200
MI	5.6/5.3	P	1.09	0.98–1.22	0.11	35.8
		SGS	1.18	0.85–1.63	0.309
Revascularization	1.9/1.6	P	1.23	0.98–1.55	0.077	27.8
		SGS	0.86	0.41–1.80	0.65
Major bleeding	3.1/3.8	P	0.80	0.70–0.92	0.001	63.5
		SGS	0.80	0.54–1.18	0.24
Minor bleeding	11.5/11.5	P	0.99	0.89–1.10	0.810	60.6
		SGS	0.94	0.74–1.20	0.591
NACE	10.3/11.3	P	0.91	0.84–0.99	0.028	67.4
		SGS	0.81	0.65–1.00	0.051

CI = Confidence interval; MACE = major adverse cardiac events; MI = myocardial infarction; NACE = net adverse clinical events; OR = odds ratio; P = Peto method; SGS = Shuster, Guo, and Skyler method; UFH = unfractionated heparin.